171 related articles for article (PubMed ID: 19737948)
21. Translocations involving anaplastic lymphoma kinase (ALK).
Duyster J; Bai RY; Morris SW
Oncogene; 2001 Sep; 20(40):5623-37. PubMed ID: 11607814
[TBL] [Abstract][Full Text] [Related]
22. Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
Thornber K; Colomba A; Ceccato L; Delsol G; Payrastre B; Gaits-Iacovoni F
Oncogene; 2009 Jul; 28(29):2690-6. PubMed ID: 19503098
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic lymphoma kinase proteins in growth control and cancer.
Pulford K; Morris SW; Turturro F
J Cell Physiol; 2004 Jun; 199(3):330-58. PubMed ID: 15095281
[TBL] [Abstract][Full Text] [Related]
24. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
Kruczynski A; Mayer P; Marchand A; Vispé S; Fournier E; Annereau JP; Brel V; Barret JM; Delsol G; Imbert T; Fahy J; Bailly C
Anticancer Drugs; 2009 Jun; 20(5):364-72. PubMed ID: 19322071
[TBL] [Abstract][Full Text] [Related]
26. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
Bossi RT; Saccardo MB; Ardini E; Menichincheri M; Rusconi L; Magnaghi P; Orsini P; Avanzi N; Borgia AL; Nesi M; Bandiera T; Fogliatto G; Bertrand JA
Biochemistry; 2010 Aug; 49(32):6813-25. PubMed ID: 20695522
[TBL] [Abstract][Full Text] [Related]
27. Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).
Settleman J
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S36-41. PubMed ID: 19393834
[TBL] [Abstract][Full Text] [Related]
28. Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.
Ardini E; Magnaghi P; Orsini P; Galvani A; Menichincheri M
Cancer Lett; 2010 Dec; 299(2):81-94. PubMed ID: 20934803
[TBL] [Abstract][Full Text] [Related]
29. Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to date.
Lowe EJ; Lim MS
Paediatr Drugs; 2013 Jun; 15(3):163-9. PubMed ID: 23696342
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
Webb TR; Slavish J; George RE; Look AT; Xue L; Jiang Q; Cui X; Rentrop WB; Morris SW
Expert Rev Anticancer Ther; 2009 Mar; 9(3):331-56. PubMed ID: 19275511
[TBL] [Abstract][Full Text] [Related]
31. Flotillin-1 regulates oncogenic signaling in neuroblastoma cells by regulating ALK membrane association.
Tomiyama A; Uekita T; Kamata R; Sasaki K; Takita J; Ohira M; Nakagawara A; Kitanaka C; Mori K; Yamaguchi H; Sakai R
Cancer Res; 2014 Jul; 74(14):3790-801. PubMed ID: 24830726
[TBL] [Abstract][Full Text] [Related]
32. Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment options.
Miething C; Peschel C; Duyster J
Curr Drug Targets; 2006 Oct; 7(10):1329-34. PubMed ID: 17073594
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.
Huang H
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400214
[TBL] [Abstract][Full Text] [Related]
34. In this issue: Tec kinases in the crosshairs.
Faris M; Bot A
Int Rev Immunol; 2012 Apr; 31(2):85-6. PubMed ID: 22449070
[TBL] [Abstract][Full Text] [Related]
35. ALK-driven tumors and targeted therapy: focus on crizotinib.
Murga-Zamalloa C; Lim MS
Pharmgenomics Pers Med; 2014; 7():87-94. PubMed ID: 24715763
[TBL] [Abstract][Full Text] [Related]
36. ALK inhibitors in lung cancer.
Heath E
Clin Adv Hematol Oncol; 2009 Oct; 7(10):649-50. PubMed ID: 20040904
[No Abstract] [Full Text] [Related]
37. Optimizing targeted cancer therapy: towards clinical application of systems biology approaches.
Sikkema AH; den Dunnen WF; Diks SH; Peppelenbosch MP; de Bont ES
Crit Rev Oncol Hematol; 2012 May; 82(2):171-86. PubMed ID: 21641230
[TBL] [Abstract][Full Text] [Related]
38. [Oncogenic mutations of ALK are associated with tumorigenesis of neuroblastoma].
Takita J; Ogawa S
Tanpakushitsu Kakusan Koso; 2009 May; 54(6):742-7. PubMed ID: 19462760
[No Abstract] [Full Text] [Related]
39. The non-receptor tyrosine kinase ACK: regulatory mechanisms, signalling pathways and opportunities for attACKing cancer.
Fox M; Crafter C; Owen D
Biochem Soc Trans; 2019 Dec; 47(6):1715-1731. PubMed ID: 31845724
[TBL] [Abstract][Full Text] [Related]
40. Emerging Roles of ALK in Immunity and Insights for Immunotherapy.
Wang L; Lui VWY
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32059449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
